WO2024231348 - SLC4A4/NBCE1 INHIBITORS
National phase entry is expected:
Publication Number
WO/2024/231348
Publication Date
14.11.2024
International Application No.
PCT/EP2024/062462
International Filing Date
06.05.2024
Title **
[English]
SLC4A4/NBCE1 INHIBITORS
[French]
INHIBITEURS DE SLC4A4/NBCE1
Applicants **
VIB VZW
Suzanne Tassierstraat 1
9052 Gent, BE
KATHOLIEKE UNIVERSITEIT LEUVEN
KU LEUVEN R&D
Waaistraat 6 - bus 5105
3000 Leuven, BE
VRIJE UNIVERSITEIT BRUSSEL
Pleinlaan 2
1050 Brussel, BE
Inventors
MAZZONE, Massimiliano
c/o VIB-KU Leuven Center for Cancer Biology
Herestraat 49 - B912
3000 Leuven, BE
ORBAN, Marie-Pauline
c/o VIB-KU Leuven Center for Cancer Biology
Herestraat 49 - B912
3000 Leuven, BE
BRUNNER, Janine
VIB-VUB Center for Structural Biology
Pleinlaan 2
1050 Brussel, BE
SCHENK, Stephan
c/o VIB-VUB Center for Structural Biology
Pleinlaan 2
1050 Brussel, BE
DOMBRECHT, Bruno
c/o VIB vzw
Suzanne Tassierstraat 1
9052 Genr, BE
LANGENBERG, Tobias
c/o VIB vzw
Suzanne Tassierstraat 1
9052 Gent, BE
CURCIO, Michele
c/o VIB vzw
Suzanne Tassierstraat 1
9052 Gent, BE
HASSANZADEH GHASSABEH, Gholamreza
c/o VIB Nanobody Core
Pleinlaan 2
1050 Brussel, BE
Priority Data
23172907.0
11.05.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1760 | |
| EPO | Filing, Examination | 7116 | |
| Japan | Filing | 530 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5485 |
Total: 15466 USD
Abstract[English]
The disclosure relates to the compounds selectively inhibiting Solute Carrier Family 4 member 4/ Electrogenic Sodium Bicarbonate Cotransporter 1 (SLC4A4/NBCe1). More in particular, said compounds are SLC4A4/NBCe1-inhibiting single domain antibodies, compounds comprising at least one CDR polypeptide of a SLC4A4/NBCe1-inhibiting single domain antibody, and compounds comprising a SLC4A4/NBCe1-inhibiting single domain antibody. Applications of compounds inhibiting SLC4A4/NBCe1 are likewise included.[French]
La divulgation concerne des composés inhibant sélectivement l'élément 4 de la famille 4 des porteurs de soluté/le cotransporteur 1 de bicarbonate de sodium électrogène (SLC4A4/NBCe1). Plus particulièrement, lesdits composés sont des anticorps à domaine unique inhibant SLC4A4/NBCe1, des composés comprenant au moins un polypeptide CDR d'un anticorps à domaine unique inhibant SLC4A4/NBCe1, et des composés comprenant un anticorps à domaine unique inhibant SLC4A4/NBCe1. Des utilisations des composés inhibant SLC4A4/NBCe1 sont également divulguées.